Michael Feld Sells Shares of Becton, Dickinson
Becton, Dickinson's EVP Michael Feld sold 75 shares in a planned move.
Key Points
- Michael Feld, EVP and Chief Revenue Officer at Becton, Dickinson, sold 75 shares at $152.8 each on June 26, 2026, totaling $11,460.
- Becton, Dickinson's stock traded near $151.38 with a market cap of $41.7 billion and a P/E ratio of 26.37.
- Analysts from Barclays and Argus Research maintain a 'buy' rating, with price targets of $204 and $180, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Michael Feld, Executive Vice President and Chief Revenue Officer at Becton, Dickinson and Company, sold 75 shares of the company in a planned transaction on June 26, 2026. The shares were sold at an average price of $152.8 each, totaling approximately $11,460.
Insider Buying and Selling at Becton, Dickinson and Company
In addition to Michael Feld's recent sale, several other insiders have been active. Michael David Garrison, EVP & President of Medical Essentials and BioPharma, sold 1,100 shares at $145.66 on June 24 and another 1,100 shares at $151.48 on June 10, both as planned transactions. Thomas Polen Jr., Chairman, CEO, and President, executed multiple sales on June 1, including 17,445 shares at $146.15 and 2,764 shares at $146.35, with some under planned trading arrangements.
Becton, Dickinson and Company Stock Down 17.7%
Shares of NYSE:BDX traded near $151.38 on Saturday. Becton, Dickinson has a market cap of about $41.7 billion and a P/E ratio of 26.37, with a forward P/E of 11.31. The stock has a 52-week low of $127.59 and a high of $187.35. Its 50-day moving average stands at $148.22, while the 200-day moving average is $153.98. The company's debt-to-equity ratio is 71.60, indicating a moderate level of leverage.
$BDX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 11, 2026, Barclays maintained its 'buy' rating on Becton, Dickinson with a price target of $204. Argus Research also maintained a 'buy' rating, setting a target of $180 on March 23, 2026. Wells Fargo and TD Cowen both maintain a 'hold' rating, with targets of $161 and $163, respectively. The overall analyst consensus suggests a 'buy' with a mean target price of $177.75 based on 12 analyst opinions.
About Becton, Dickinson and Company
Becton, Dickinson and Company, headquartered in Franklin Lakes, New Jersey, is a global leader in the medical technology sector. The company develops, manufactures, and sells a wide range of medical supplies and devices, laboratory equipment, and diagnostic products. Its products serve healthcare institutions, physicians, and researchers worldwide. Led by CEO Thomas E. Polen Jr., Becton, Dickinson employs approximately 60,000 people and operates through various segments including Medical Essentials, Connected Care, and Life Sciences.
Bottom Line
Michael Feld's planned sale of Becton, Dickinson shares is part of regular insider activity at the company. Investors keep a close eye on such transactions as they can provide insights into management's view of the company's future. However, it's important to remember that these sales are often pre-arranged and not necessarily indicative of the insider's outlook. Becton, Dickinson continues to be a significant player in the healthcare sector, with analysts maintaining a positive outlook.
Get Becton, Dickinson and Company alerts
New 13F filings, insider trades, and analyst moves on $BDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.